SciELO - Scientific Electronic Library Online

 
vol.17 issue1Detection of shellfish toxins from scallops in Guangzhou seafood marketLeptospiral antibodies in wild boars (Sus scrofa) bred in Brazil author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Journal of Venomous Animals and Toxins including Tropical Diseases

On-line version ISSN 1678-9199

J. Venom. Anim. Toxins incl. Trop. Dis vol.17 no.1 Botucatu  2011

http://dx.doi.org/10.1590/S1678-91992011000100011 

ORIGINAL PAPER

 

Neutralization of pharmacological and toxic activities of Bothrops jararacussu snake venom and isolated myotoxins by Serjania erecta methanolic extract and its fractions

 

 

Fernandes RSI; Costa TRI; Marcussi SIII; Bernardes CPI; Menaldo DLI; Rodriguéz Gonzaléz II III; Pereira PSII; Soares AMI

IDepartment of Clinical, Toxicological and Bromatological Analysis, School of Pharmaceutical Sciences, University of São Paulo, USP, Ribeirão Preto, São Paulo State, Brazil
IIBiotechnology Unit, University of Ribeirão Preto, UNAERP, Ribeirão Preto, São Paulo State, Brazil
IIIDepartment of Chemistry, Federal University of Lavras, UFLA, Lavras, Minas Gerais State, Brazil

Correspondence to

 

 


ABSTRACT

Most of the snakebites recorded in Brazil are caused by the Bothrops genus. Given that the local tissue damage caused by this genus cannot be treated by antivenom therapy, numerous studies are focusing on supplementary alternatives, such as the use of medicinal plants. Serjania erecta has already demonstrated anti-inflammatory, antiseptic and healing properties. In the current study, the aerial parts of S. erecta were extracted with methanol, then submitted to chromatographic fractionation on a Sephadex LH20 column and eluted with methanol, which resulted in four main fractions. The crude extract and fractions neutralized the toxic activities of Bothrops jararacussu snake venom and isolated myotoxins (BthTX-I and II). Results showed that phospholipase A2, fibrinogenolytic, myotoxic and hemorrhagic activities were inhibited by the extract. Moreover, the myotoxic and edematous activities induced by BthTX-I, and phospholipase A2 activity induced by BthTX-II, were inhibited by the extract of S. erecta and its fraction. The clotting time on bovine plasma was significantly prolonged by the inhibitory action of fractions SF3 and SF4. This extract is a promising source of natural inhibitors, such as flavonoids and tannins, which act by forming complexes with metal ions and proteins, inhibiting the action of serineproteases, metalloproteases and phospholipases A2.

Key words: medicinal plants, antiophidian properties, Serjania erecta, Bothrops jararacussu snake venom, myotoxins.


 

 

INTRODUCTION

Snake venoms are a complex mixture of toxic enzymes and proteins such as phospholipases A2, myotoxins, hemorrhagic metalloproteases, clotting serineproteases, neurotoxins, cytotoxins and others. In Brazil, Bothrops and Crotalus snakes are responsible for most ophidian envenomations, which induce mainly local tissue damage such as hemorrhage, necrosis, edema and alterations in blood coagulation. Snakebite envenomations are frequently treated with parenteral administration of horse- or sheep-derived antivenoms aiming at the neutralization of toxins. But despite the success of serum therapy, it is important to search for different venom inhibitors, either synthetic or natural, which would complement the action of antivenoms, particularly in relation to the neutralization of local tissue damage (1). Plant extracts constitute an extremely rich source of pharmacologically active compounds, and a number of extracts has been shown to act against snake venom (2). The medicinal value associated with a plant can be confirmed by the successful use of its extract on snakebite wounds (3-6). Application of medicinal plants with anti-snake-venom activities might be useful as first aid treatment for victims of snakebites, which is particularly important in local areas where antivenoms are not readily available (7-10).

In many countries, plant extracts have been used traditionally in the treatment of snakebite envenomations. Thus, vegetal extracts have been found to constitute an excellent alternative with a range of anti-snake-venom properties. However, in most cases, scientific evidence of their antiophidian activity is still needed. Several plants have already shown antiophidian activity and the Brazilian flora has a wide variety of medicinal plants with anti-snake-venom potential (2, 3, 5, 6, 11).

The vegetal kingdom is the main source of pharmacologically active compounds (12). The Sapindaceae family is widely distributed in the tropical regions of the world and some species are found in Brazil, including Serjania erecta Radlk, commonly called retrato de teiú, cinco-folhas or cipó-cinco-folhas (13). The popular use of S. erecta in Brazil is related to the treatment of inflammatory and ulcerative diseases, but several studies showed that different species of the Serjania genus and some of their isolated compounds present analgesic, antibacterial, antifungal, molluscicidal activity and anti-inflammatory effect (14-17). Phytochemical screening tests have demonstrated the presence of alkaloids, saponins, flavonoids, tannins, triterpenoids, steroids, catechins, coumarins, anthranoids and quinines in S. erecta extract (16). The present study aimed to investigate the healing properties of S. erecta against the toxic effects induced by Bothrops jararacussu snake venom.

 

MATERIALS AND METHODS

Reagents and Animals

Snake venoms were purchased from the Bioactive Proteins Serpentarium, Batatais, São Paulo state, Brazil. BthTX-I and II were isolated from Bothrops jararacussu snake venom (Bjussu) as previously described (18). Male Swiss mice (18-25 g) were obtained from the animal house at the School of Pharmaceutical Sciences of Ribeirão Preto, São Paulo state, Brazil. Experiments reported in this study were performed after approval by the Institutional Ethics Committee of the University of São Paulo (protocol n. 07.1.202.53.1).

Plant Material and Chromatographic Fractionation

Plant material of Serjania erecta was collected in Altinópolis (from a rural area in the state of São Paulo). A voucher specimen (n. HPMU 835) has been deposited at the Medicinal Plant Herbarium of the Biotechnology Unit of the University of Ribeirão Preto (UNAERP), Ribeirão Preto, SP, Brazil. Aerial parts (stem and leaf) were dried in an oven at 60°C and plant material was pulverized into a dry powder and extracted by applying methanol for three days by maceration. The extract was then concentrated at a reduced temperature (50°C). The crude extract (5 g) was dissolved in methanol and subjected to chromatographic fractionation on a Sephadex LH20 column (110 x 3 cm) and eluted with methanol. This fractionation resulted in four main fractions that were evaluated by phytochemical screening tests. The fractions were evaporated under reduced pressure and the concentrations were expressed in terms of dry weight.

Phospholipase A2 Activity

Phospholipase A2 activity was measured via an indirect hemolytic assay on agarose-erythrocyte-egg yolk gel plates, following methods described by Gutiérrez et al. (19). The minimum indirect hemolytic dose (MIHD) of BthTX-II or B. jararacussu snake venom (10 μg) induced hemolytic halos after incubation of plates for 18 hours at 37°C. The extracts and venom/toxin (1:30, w/w) were preincubated for 30 minutes at 37°C and the anti-phospholipase A2 potential of the extracts was measured after 18 hours of plate incubation at 37°C. This experiment was done in triplicate. Crude venom and phosphate buffered saline (PBS) were used as controls.

Fibrinogenolytic Activity

The fibrinogenolytic activity was evaluated as previously described (20). Bovine fibrinogen (40 μg) was incubated at 37°C for one hour with 10 μg of B. jararacussu snake venom preincubated with the extracts (1:30, w/w) for 30 minutes at 37°C and the reaction was stopped with 25 μL of 0.5M Tris-HCl buffer (pH 6.5) containing 2% (w/v) SDS, 3.5% (v/v) β-mercaptoethanol and 0.05 % (w/v) bromophenol blue. The samples were analyzed by 12% (w/v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

Edema-Inducing Activity

Edema was evaluated by subplantar injection of BthTX-I (10 μg) in the right paw of male Swiss mice (18-25 g, n = 5). Inhibition studies were performed after preincubation of venom/toxin with the extracts at a 1:30 (w/w) ratio. Control animals received an injection of PBS under identical conditions. The progression of edema was evaluated by measuring the paw with a low-pressure pachymeter (Mitutoyo, Japan) at four time intervals (0, 30, 60 and 180 minutes) upon and after injection (21). Activity was expressed as the mean of percent edema values induced by the snake venoms in the absence and presence of the plant extracts and their fractions.

Myotoxic Activity

Male Swiss mice (18-25 g, n = 5) were injected intra-muscularly (IM) in the right gastrocnemius muscle with samples containing doses of 10 μg of BthTX-I or B. jararacussu snake venom. Following incubation of S. erecta methanolic extract and fractions with the crude venoms or isolated toxins for 30 minutes at 37°C, the mixtures of myotoxin/inhibitors (1:30, w/w) were then evaluated. Controls received venom/toxin. Mice were bled from the tail three hours after injections and blood was collected into heparinized capillary tubes. Plasma creatine kinase (CK) activity was determined using the kit CK-UV (Bioclin, Brazil) (22). The myotoxic activity was expressed in U/L.

Hemorrhagic Activity

Hemorrhagic activity was assessed according to the method of Gutiérrez et al. (23). The minimum hemorrhagic dose (MHD) of B. jararacussu snake venom (10 μg) was determined by intradermal (ID) injection into marked positions on the shaved dorsal skin of mice (18-25g, n = 5). The inhibition of hemorrhagic activity was assayed by ID injection of venom preincubated with the extracts (30 minutes at 37°C, 1:30, w/w) in the back of mice. After three hours, mice were sacrificed with CO2, the dorsal skin was removed and the diameter of the hemorrhagic lesion on the inner surface of the skin was measured. Hemorrhagic activity was expressed as the mean of the hemorrhagic halos (in mm). Crude venom was used as control.

Coagulant Activity

A minimum coagulant dose (MCD) was defined as the amount of B. jararacussu venom that clots 200 μL of bovine plasma in 120 seconds (24). Briefly, 200 μL aliquots of plasma (n = 3) were incubated with 20 μg of venom preincubated with the extracts (30 minutes at 37°C, 1:30, w/w) and clotting times were recorded. Control tubes included plasma with PBS plus calcium, extracts/fractions alone and with venom. Coagulant activity was expressed as the mean coagulation time (in minutes) induced by the snake venom in the absence and presence of extracts and fractions.

Statistical Analysis

The statistical significance of differences between groups was evaluated using one-way analysis of variance (ANOVA). A p-value < 0.05 was considered significant. Data are shown as mean ± standard deviation (SD).

 

RESULTS AND DISCUSSION

The fractionation of methanolic extract of S. erecta (EFMeOH) on Sephadex LH20 resulted in four main fractions: SF1 (18.2%), SF2 (42%), SF3 (19.6%) and SF4 (16.2%). These fractions were subjected to phytochemical screening tests that revealed the presence of saponins, terpenes, flavonoids and tannins, respectively (results not shown).

Phospholipases A2 (PLA2s) constitute one of the widely distributed enzyme groups that hydrolyze glycerophospholipids at the sn-2 position of the glycerol backbone, thus releasing lysophospholipids and fatty acids. Snake venom PLA2s are known to induce various pathological effects in experimental animal models. PLA2 activity induced by B. jararacussu snake venom (Figure 1 - A) and myotoxin BthTX-II (Figure 1 - B) were inhibited at different levels by the methanolic extract of S. erecta and its fractions. For example, the PLA2 activity induced by BthTX-II was almost completely inhibited by the action of fractions SF3 and SF4. The SF3 fraction is rich in flavonoids, compounds known to possess anti-inflammatory activity, while the SF4 fraction is rich in tannins, a class of compounds that can precipitate proteins. The fact that the fractions SF3 and SF4 have shown a greater efficiency in the inhibition of BthTX-II-induced PLA2 activity and lesser action against the PLA2 activity induced by crude venom may be related to the presence of other toxic components in the venom, which are also responsible for this activity. Several exogenous agents from medicinal plants such as flavonoids, aristolochic acid and coumestan are also known to inhibit PLA2 activity (3, 25, 26).

Some compounds from snake venoms show large diversity in their proteolytic activity and fibrinogen is one of their main substrates. These proteases can convert fibrinogen into fibrin. Once again, fractions SF3 and SF4 were capable of preventing the complete degradation of the fibrinogen chains (Figure 2 - A). The fractions effectively antagonized the defibrinogenating activity induced by B. jararacussu snake venom. Previously studied plant extracts also revealed efficient results in the protection of fibrinogen, including Bauhinia forficata (27), Citrus limon and Ficus nymphaeifolia (4, 9).

The formation of mast-cell-mediated edema in the presence of PLA2s is the result of enzymatic activity. Nevertheless, venom PLA2s with no enzymatic activity activate mast cells by an independent mechanism of catalytic activity (28). In assays of the edema-inducing activity (Figure 2 - B), the methanolic extract of S. erecta and its fractions inhibited BthTX-I diminishing the formation of edema. Other plant extracts also inhibited the formation of edema-inducing activity, such as Mandevilla velutina, Cordia verbanacea, Mikania glomerata and Blutaparon portulacoides (29-32).

Local tissue damage induced by Bothrops venoms is caused by hemorrhage, proteolysis, myonecrosis and edema. Myotoxic activity is the result of the action of hemorrhagic metalloproteases or myotoxic PLA2s (33). The myotoxicity induced by B. jararacussu snake venom (Figure 3 - A) and its isolated myotoxin, BthTX-I (Figure 3 - B), was significantly decreased by preincubation with the methanolic extract of S. erecta and its fractions. Some medicinal plants with antiophidian activity also showed promising results in the inhibition of myonecrosis induced by snake venom, including Calendula officinalis (34) and Tabernaemontana catharinensis (35).

The methanolic extract of S. erecta and its fractions decreased the hemorrhagic activity induced by B. jararacussu venom (Figure 3 - C). One of the most beneficial first-aid treatments in viperid snakebites is the neutralization of hemorrhagic symptoms. These results suggest an interaction between the extract components and metalloproteases, which inhibited their hemorrhagic activities. Antiophidian plants with antihemorrhagic properties have been identified in different studies as Calendula officinalis, Baccharis trimera, Mikania glomerata, Casearia sylvestris and Eclipta alba (26, 31, 34, 36, 37).

Bothrops venom usually produces hemorrhages due to a considerable degradation of fibrinogen and other clotting factors which prevents clot formation (1). The methanolic extract of S. erecta and its fractions were able to delay the clotting time of citrated plasma after addition of the venoms at a 1:30 ratio, but fractions SF3 and SF4 were more efficient in that, since they considerably inhibited the coagulant activity of B. jararacussu venom (Table 1). Results with fractions SF3 and SF4, rich in flavonoids and tannins, showed that these compounds act as powerful inhibitors of the hemorrhagic and clotting activity, probably due to interaction with metalloproteases and thrombin-like enzymes, respectively. Studies of several plants (Heliconia curtispatha, Pleopeltis percussa, Brownea rosademonte, Bixa orellana, Trichomanes elegans, Struthanthus orbiculareis and Casearia sylvestris) describe the inhibitory effect of all or part of the coagulant activity of snake venoms from B. asper, B. jararacussu, B. pirajai, B. neuwiedi, B. moojeni and C. d. terrificus (9, 38, 39).

 

CONCLUSION

Ophidian accidents caused by Bothrops snakes are characterized by prominent local tissue damage due to myonecrosis, hemorrhage and edema, and unfortunately antivenoms are unable to antagonize the myotoxic effects of phospholipase myotoxins or the hemorrhagins in the venom (1). Vegetal extracts have served as alternatives for treatment or as an additional therapy for local tissue damage, since they are sources of chemical compounds with several pharmacological activities of medical-scientific interest. Folk medicine shows several examples of claimed medicinal plants including the popular use of S. erecta for treating inflammatory and ulcerative diseases. Possibly its antiophidian activity is due to the presence of phenolic compounds such as flavonoids and tannins. These compounds present the ability to inhibit toxic activities of B. jararacussu snake venom and the isolated myotoxins BthTX-I and II. Other studies were also able to demonstrate the role of phenolic compounds in inhibiting the effects of snake venoms (40-42). Furthermore, possible isolated compounds can be used as molecular models of inhibitors for the development of new therapeutic agents in treatment of ophidian accidents. This extract is a promising source of natural inhibitors, such as flavonoids and tannins, which probably act by forming complexes with metal ions and proteins that inhibit the action of serine proteases involved in blood coagulation disturbances and metalloproteases responsible for hemorrhagic processes and enzymatic activity of phospholipases A2.

 

ACKNOWLEDGEMENTS

The authors are grateful for the financial support provided by the Coordination for the Improvement of Higher Education Personnel (CAPES), the National Council for Scientific and Technological Development (CNPq) and the State of São Paulo Research Foundation (FAPESP); and for the technical assistance of all students and technicians (Fernanda Romano Suzano and Sarazate I. V. Pereira) who collaborated in this work. The authors also thank the University of Ribeirão Preto.

 

REFERENCES

1. Cardoso JLC, França FOS, Wen FH, Malaque CMS, Haddad Jr V. Animais peçonhentos no Brasil: biologia, clínica e terapêutica dos acidentes. São Paulo: Ed. Sarvier, 2003. 468 p.         [ Links ]

2. Martz W. Plants with a reputation against snakebite. Toxicon. 1992;30(10):1131-42.         [ Links ]

3. Mors WB, Nascimento MC, Pereira BM, Pereira NA. Plant natural products active against snake bite - the molecular approach. Phytochemistry. 2000;55(6):627-42.         [ Links ]

4. Otero R, Fonnegra R, Jiménez SL, Núñes V, Evans N, Alzate SP, et al. Snakebites and ethnobotany in the northwest region of Colombia. Part I: traditional use of plants. J Ethnopharmacol. 2000;71(3):493-504.         [ Links ]

5. Soares AM, Januário AH, Lourenço MV, Pereira AMS, Pereira PS. Neutralizing effects of Brazilian plants against snake venoms. Drugs Fut. 2004;29(11):1105-17.         [ Links ]

6. Soares AM, Marcussi S, Fernandes RS, Menaldo DL, Costa TR, Lourenço MV, et al. Medicinal plant extracts and molecules as the source of new anti-snake venom drugs. In: Rahman A, Reitz AB, Choudhary MI, editors. Frontiers in medicinal chemistry. Karachi-Pakistan: Bentham Science Publishers; 2009. 309-46 p. 4 vol.         [ Links ]

7. Otero R, Núñez V, Jiménez SL, Fonnegra R, Osorio RG, García ME, et al. Snakebites and ethnobotany in the northwest region of Colombia. Part II: neutralization of lethal and enzymatic effects of Bothrops atrox venom. J Ethnopharmacol. 2000;71(3):505- 11.         [ Links ]

8. Otero R, Núñez V, Borona J, Fonnegra R, Jiménez SL, Osório RG, et al. Snakebites and ethnobotany in the northwest region of Colombia. Part III: neutralization of haemorrhagic effect of Bothrops atrox venom. J Ethnopharmacol. 2000;73(1-2):233-41.         [ Links ]

9. Núñez V, Otero R, Barona J, Saldarriaga M, Osório RG, Fonnegra R, et al. Neutralization of the edema-forming, defibrinating and coagulant effects of Bothrops asper venom by extracts of plants used by healers in Colombia. Braz J Med Biol Res. 2004;37(7):969-77.         [ Links ]

10. Sánchez EE, Rodríguez-Acosta A. Inhibitors of snake venoms and development of new therapeutics. Immunopharmacol Immunotoxicol. 2008;30(4):647-78.         [ Links ]

11. De Paula RC, Sanchez EF, Costa TR, Martins CHG, Pereira PS, Lourenço MV, et al. Antiophidian properties of plant extracts against Lachesis muta venom. J Venom Anim Toxins incl Trop Dis. 2010;16(2):311-23.         [ Links ]

12. Cordell GA, Colvard MD. Some thoughts on the future of ethnopharmacology. J Ethnopharmacol. 2005;100(1-2):5-14.         [ Links ]

13. Guarim-Neto G, Santana SR, Silva JVB. Notas etnobotânicas de espécies de Sapindaceae jussieu. Acta Bot Bras. 2000;14(3):327-34.         [ Links ]

14. di Stasi LC, Costa M, Mendaçolli SL, Kirizawa M, Gomes C, Trolin G. Screening in mice of some medicinal plants used for analgesic purposes in the state of São Paulo. J Ethnopharmacol. 1988;24(2-3):205-11.         [ Links ]

15. Ekabo OA, Farnsworth NR, Henderson TO, Mao G, Mukherjee R. Antifungal and molluscicidal saponins from Serjania salzmanniana. J Nat Prod. 1996;59(4):431-5.         [ Links ]

16. de Lima MR, de Souza Luna J, dos Santos AF, de Andrade MC, Sant'ana, AE, Genet JP, et al. Anti-bacterial activity of some Brazilian medicinal plants. J Ethnopharmacol. 2006;105(1-2):137-47.         [ Links ]

17. Gomig F, Pietrovski EF, Guedes A, Dalmarco EM, Calderari MT, Guimarães CL, et al. Topical anti-inflammatory activity of Serjania erecta Radlk (Sapindaceae) extracts. J Ethnopharmacol. 2008;118(2):220-4.         [ Links ]

18. Andrião-Escarso SH, Soares AM, Rodrigues VM, Ângulo Y, Díaz C, Lomonte B, et al. Myotoxic phospholipases A2 in Bothrops snake venoms: effect of chemical modifications on the enzymatic and pharmacological properties of bothropstoxins from Bothrops jararacussu. Biochimie. 2000;82(8):755-63.         [ Links ]

19. Gutiérrez JM, Avila C, Rojas E, Cerdas L. An alternative in vitro method for testing the potency of the polyvalent antivenom produced in Costa Rica. Toxicon. 1988;26(4):411-3.         [ Links ]

20. Rodrigues VM, Soares AM, Guerra-Sá R, Rodrigues V, Fontes MRM, Giglio JR. Structural and functional characterization of neuwiedase, a nonhemorrhagic fibri(ogen)olytic metalloprotease from Bothrops neuwiedi snake venom. Arch Biochem Biophys. 2000;381(2):213-24.         [ Links ]

21. Soares AM, Andrião-Escarso SH, Angulo Y, Lomonte B, Gutiérrez JM, Marangoni S, et al. Structural and functional characterization of a myotoxin I, a Lys49 phospholipase A(2) homologue from Bothrops moojeni (caissaca) snake venom. Arch Biochem Biophys. 2000;373(1):7-15.         [ Links ]

22. Soares AM, Andrião-Escarso SH, Bortoleto RK, Rodrigues-Simioni L, Ward RJ, Arni RK, et al. Dissociation of enzymatic and pharmacological activities of two piratoxins-I and -III, two myotoxic phospholipases A2, from Bothrops pirajai snake venom. Arch Biochem Biophys. 2001;387(2):188-96.         [ Links ]

23. Gutiérrez JM, Gené JA, Rojas G, Cerdas L. Neutralization of proteolytic and hemorrhagic activities of Costa Rica snake venoms by a polyvalent antivenom. Toxicon. 1985;23(6):887-93.         [ Links ]

24. Gené JA, Roy A, Rojas G, Gutiérrez JM, Cerdas L. Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom. Toxicon. 1989;27(8):841-8.         [ Links ]

25. Vishwanath BS, Gowda TV. Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities. Toxicon. 1987;25(9):929-37.         [ Links ]

26. Diogo LC, Fernandes RS, Marcussi S, Menaldo DL, Roberto PG, Matrangulo PV, et al. Inhibition of snake venoms and phospholipases A2 by extracts from native and genetically modified Eclipta alba: isolation of active coumestans. Basic Clin Pharmacol Toxicol. 2009;104(4):293-9.         [ Links ]

27. Oliveira CZ, Maiorano VA, Marcussi S, Sant'Ana CD, Januário AH, Lourenço MV, et al. Anticoagulant and antifibrinogenolytic properties of the aqueous extract from Bauhinia forficata against snake venoms. J Ethnopharmacol. 2005;98(1-2):213-6.         [ Links ]

28. Marcussi S, Sant'Ana CD, Oliveira CZ, Rueda AQ, Menaldo DL, Beleboni RO, et al. Snake venom phospholipase A2 inhibitors: medicinal chemistry and therapeutic potential. Curr Top Med Chem. 2007;7(8):743-56.         [ Links ]

29. Biondo R, Pereira AM, Marcussi S, Pereira PS, França SC, Soares AM. Inhibition of enzymatic and pharmacological activities of some snake venoms and toxins by Mandevilla velutina (Apocinaceae) aqueous extract. Biochimie. 2003;85(10):1017-25.         [ Links ]

30. Ticli FK, Hage LI, Cambraia RS, Pereira PS, Magro AJ, Fontes MR, et al. Rosmarinic acid, a new snake venom phospholipases A2 inhibitor from Cordia verbenacea (Boraginaceae): antiserum action potentiation and molecular interaction. Toxicon. 2005;46(3):318-27.         [ Links ]

31. Maiorano VA, Marcussi S, Daher MA, Oliveira CZ, Couto LB, Gomes OA, et al. Antiophidian properties of the aqueous extract of Mikania glomerata. J Ethnopharmacol. 2005;102(3):364-70.         [ Links ]

32. Pereira IC, Barbosa AM, Salvador MJ, Soares AM, Ribeiro W, Cogo JC, et al. Anti-inflamatory activity of Blutaparon portulacoides ethanolic extract against the inflammatory reaction induced by Bothrops jararacussu venom and isolated myotoxins BthTX-I and II. J Venom Anim Toxins incl Trop Dis. 2009;15(3):527-45.         [ Links ]

33. Gutiérrez JM, Lomonte B. Phospholipase A2 myotoxins from Bothrops snake venoms. In: Venom phospholipase A2 enzymes: structure, function, and mechanism. England, UK: John Wiley & Sons, 1997. 321-52 p.         [ Links ]

34. Melo MM, Merfort I, Habermehl GG, Ferreira KM. Uso de extratos de plantas no tratamento local de pele de coelho após envenenamento botrópico experimental. J Bras Fitomed. 2003;1(1):100-6.         [ Links ]

35. Veronese EL, Esmeraldino LE, Trombone AP, Santana AE, Bechara GH, Kettelhut I, et al. Inhibition of the myotoxic activity of Bothrops jararacussu venom and its two major myotoxins, BthTX-I and BthTX-II, by the aqueous extract of Tabernaemontana catharinensis A. DC. (Apocynaceae). Phytomedicine. 2005;12(1-2):123-30.         [ Links ]

36. Januário AH, Marcussi S, Santos SL, Mazzi MV, Sampaio SV, Pietro RC, et al. Neo-clerodane diterpenoid, a new metalloprotease snake venom inhibitor from Baccharis trimera (Asteradeae): anti-proteolytic and anti-hemorrhagic properties. Chem Biol Interact. 2004;150(3):243-51.         [ Links ]

37. Cavalcante WL, Campos TO, Dal Pai-Silva M, Pereira PS, Oliveira CZ, Soares AM, et al. Neutralization of snake venom phospholipase A2 toxins by aqueous extract of Casearia sylvestris (Flacourtiaceae) in mouse neuromuscular preparation. J Ethnopharmacol. 2007;112(3):490-7.         [ Links ]

38. Borges MH, Soares AM, Rodrigues VM, Andrião-Escarso SH, Diniz H, Hamaguchi A, et al. Effects of aqueous extract of Casearia sylvestris (Flacourtiaceae) on actions of snake and bee venoms and on activity of phospholipases A2. Comp Biochem Physiol B Biochem Mol Biol. 2000;127(1):21-30.         [ Links ]

39. Borges MH, Soares AM, Rodrigues VM, Oliveira F, Franshechi AM, Rucavado A, et al. Neutralization of proteases from Bothrops snake venoms by the aqueous extract from Casearia sylvestris (Flacourtiaceae). Toxicon. 2001;39(12):1863-9.         [ Links ]

40. Pithayanukul P, Ruenraroengsak P, Bavovada R, Pakmanee N, Suttisri R, Saen-oon S. Inhibition of Naja kaouthia venom activities by plant polyphenols. J Ethnopharmacol. 2005;97(3):527-33.         [ Links ]

41. Samy RP, Thwin MM, Gopalakrishnakone P, Ignacimuthu S. Ethnobotanical survey of folk plants for the treatment of snakebites in Southern part of Tamilnadu, India. J Ethnopharmacol. 2008;115(2):302-12.         [ Links ]

42. Nishijima CM, Rodrigues CM, Silva MA, Lopes-Ferreira M, Vilegas W, Hiruma-Lima CA. Anti-hemorrhagic activity of four Brazilian vegetable species against Bothrops jararaca venom. Molecules. 2009;14(3):1072-80.         [ Links ]

 

 

Correspondence to:
Renata S. Fernandes
Departamento de Análises Clínicas
Toxicológicas e Bromatológicas
Faculdade de Ciências Farmacêuticas de Ribeirão Preto
Universidade de São Paulo
Ribeirão Preto, SP, Brasil
Phone: +55 16 3602 4714
Email: renatarsf@usp.br

Submission status
Received: October 29, 2010.
Accepted: January 25, 2011.
Abstract published online: January 26, 2011.
Full paper published online: February 28, 2011.
Financial source
The Coordination for the Improvement of Higher Education Personnel (CAPES), the National Council for Scientific and Technological Development (CNPq) and the State of São Paulo Research Foundation (FAPESP) provided the financial grants.

 

 

Conflicts of interest
There is no conflict.
Ethics committee approval
The present study was approved by the Institutional Ethics Committee of the University of São Paulo (protocol number 07.1.202.53.1)

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License